Transcript
Neal Bhatia (00:07):
Hi, I am Dr. Neal Bhatia. I'm Chief Medical Editor of Practical Dermatology and Director of Clinical Dermatology at Therapeutics Clinical Research in San Diego, California. The most important part about what we are doing in clinical trials as well as in the clinic is we have to remember the pipeline. And again, supporting research and development comes back to, again, using drugs that work. They may be, again, something we have to fight for, but medical dermatology deserves that, as do our patients. We're seeing a lot of new innovations such as the FASN inhibitor, Denifanstat, coming to acne from what was just in MASH. We're seeing a lot of new, again, inhibitors of STAT6 protein.
(00:41):
We're seeing different biologics that are in trials that have combinations and long-term safety, as well as some new advance in biologics that have different dosing strategies. More importantly is, again, the JAK inhibitors that we're using for alopecia areata are finding some other uses. Again, vitiligo will be coming to the market in Ritlacidinib. And of course the pipeline for a lot of the cosmeceuticals and a lot of devices is also very strong. So again, supporting research, supporting the pipeline is very critical. We're also, again, facing a shortage of dermatology investigators, and we need to cultivate a new generation of those of us who actually enjoy clinical research as well as bringing new things to the world.
